Key result
V-Wave shunt shows preliminary HF benefit but narrows or occludes in ~50% at 12 months.
Why the study?
Initial experience with the V-Wave interatrial shunt showed shunt narrowing or occlusion in up to 50% of patients at 12 months due to early valve degeneration, prompting device modifications to improve late patency.
Answers are grounded in this paper and cite their sources.
Durability concerns warrant clinical caution; leaves open whether device redesigns can sustain interatrial shunting in heart failure.
Introduction Left atrial decompression by creating an interatrial shunt has been associated with significant improvements in functional status and quality of life in patients with heart failure (HF) with reduced and preserved left ventricular ejection fraction (HFrEF, HFpEF)1. The initial experience with the V-Wave shunt (V-Wave Ltd, Caesarea, Israel) showed its safety and preliminary efficacy for treating patients with HFrEF and HFpEF2,3. However, shunt narrowing/occlusion was observed in up to 50% of the patients at 12-month follow-up, secondary to early valve degeneration3. Following this initial experience, modifications were implemented in order to improve late device patency and ...
No takes yet. Share an insight, caveat, or question.
Guimarães et al. (2020) studied advanced chronic heart failure. second-generation V-Wave system was evaluated. Initial experience with the V-Wave shunt showed safety and preliminary efficacy for heart failure, but shunt narrowing or occlusion occurred in up to 50% of patients at 12 months.
Synapse has enriched 10 related papers. Consider them for comparative context: